Oxford Asset Management’s Indaptus Therapeutics INDP Stock Holding History

Oxford Asset Management’s Portfolio INDP Stock Details INDP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-11	Closed	-$178K	–	1814
2018 Q4	$178K	Buy	+11	New	+$150K	﹤0.01%	1565
2018 Q3	–	Sell	-14	Closed	-$133K	–	1800
2018 Q2	$133K	Sell	14 -14	-50%	-$155K	﹤0.01%	1625
2018 Q1	$400K	Buy	28 +18	+180%	+$255K	0.01%	1323
2017 Q4	$116K	Buy	+10	New	+$155K	﹤0.01%	1513

Other funds holding INDP

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SAM

Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

EIM

Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Oxford Asset Management's INDP Position: Q1 2019 in Review

Oxford Asset Management sold out of Indaptus Therapeutics (INDP) in Q1 2019, closing a stake of 11 shares — an estimated $178K sold.

Oxford Asset Management first reported a position in INDP in Q4 2017 and held it in 4 quarters. The position peaked at $400K in Q1 2018. 36 funds tracked by Wall St. Rank hold INDP as of Q1 2019.

Oxford Asset Management reported no remaining Indaptus Therapeutics position as of Q1 2019 after selling out during the quarter.
Oxford Asset Management sold 11 Indaptus Therapeutics shares in Q1 2019, an estimated $178K.
Oxford Asset Management first reported a position in Indaptus Therapeutics in Q4 2017 and held it in 4 quarters.
Oxford Asset Management's Indaptus Therapeutics position peaked at $400K in Q1 2018.
36 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2019.

Based on Oxford Asset Management's 13F filing for Q1 2019, filed 15 May 2019.